FEI-Zyfer Announces Contract Awards for Approximately $6.0 Million

FEI-Zyfer Announces Contract Awards for Approximately $6.0 Million GlobeNewswire January 12, 2026 Garden Grove, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — FEI-Zyfer, Inc., a wholly-owned subsidiary of Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, is pleased to announce the receipt of contracts totaling approximately […]

HII Expands European Unmanned Operations with New Facility in Portchester, UK

HII Expands European Unmanned Operations with New Facility in Portchester, UK GlobeNewswire January 12, 2026 PORTCHESTER, United Kingdom, Jan. 12, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII), the world's leading manufacturer of autonomous surface and underwater unmanned vehicles, has doubled the size of its unmanned facility in Portchester, U.K. The enlarged facility significantly enhances and

NuPhy Launches New Focus-Driven Keyboards at CES 2026

NuPhy Launches New Focus-Driven Keyboards at CES 2026 The brand doesn't design keyboards for everyone — and that's the point. GlobeNewswire January 12, 2026 LAS VEGAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — At CES this year, keyboard and input device brand NuPhy announced its latest product lineup and made its position clear: its keyboards are

Mingteng International Expands Ongoing Strategic Collaboration with Leading NEV Top Tier Supplier in China to Support Sustainable Development

Mingteng International Expands Ongoing Strategic Collaboration with Leading NEV Top Tier Supplier in China to Support Sustainable Development GlobeNewswire January 12, 2026 WUXI, China, Jan. 12, 2026 (GLOBE NEWSWIRE) — Mingteng International Corporation Inc. (the “Company” or “Mingteng International”) (Nasdaq: MTEN), an automotive mold developer and supplier in China, today announced the deepening of its

Axe Compute (NASDAQ: AGPU) Named Sponsor of the Sequire Investor Summit Puerto Rico 2026

Axe Compute (NASDAQ: AGPU) Named Sponsor of the Sequire Investor Summit Puerto Rico 2026 GlobeNewswire January 12, 2026 San Juan, Puerto Rico, Jan. 12, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU), a next-generation computing infrastructure company focused on high-performance and AI-driven solutions, announced it will serve as a sponsor of the Sequire Investor

Instar Appoints New Partner in Montreal to Lead Quebec Expansion

Instar Appoints New Partner in Montreal to Lead Quebec Expansion GlobeNewswire January 12, 2026 TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Instar Asset Management Inc. (“Instar” or the “Company“), a Toronto-based private equity firm, is pleased to announce that Mathieu Ouellet, a seasoned investment and strategy executive, has joined the firm as a Partner. Based

Avalon GloboCare Regains Compliance with Nasdaq Stockholders’ Equity Requirement, Launches Marketing for Automated Generative AI Video Platform

Avalon GloboCare Regains Compliance with Nasdaq Stockholders' Equity Requirement, Launches Marketing for Automated Generative AI Video Platform GlobeNewswire January 12, 2026 FREEHOLD, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk GlobeNewswire January 12, 2026 First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102

Oncolytics Biotech(R) Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech(R) Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer GlobeNewswire January 12, 2026 Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan.

Scroll to Top